Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK AXL over exp |
| Therapy | Bemcentinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK AXL over exp | lung adenocarcinoma | no benefit | Bemcentinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK and overexpressing AXL did not demonstrate sensitivity to Bemcentinib (BGB-324) treatment in culture (PMID: 32558295). | 32558295 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32558295) | Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. | Full reference... |